Brazilian Journal of Pain
https://brjp.org.br/article/doi/10.5935/2595-0118.20230053-en
Brazilian Journal of Pain
Review Article

The endocannabinoid system and orofacial pains: updates and perspectives

O sistema endocanabinoide e as dores orofaciais: atualidades e perspectivas

João Paulo Colesanti Tanganeli; Denise Sabbagh Haddad; Sigmar de Mello Rode; Claudia Herrera Tambeli; Eduardo Grossmann

Downloads: 0
Views: 140

Abstract

BACKGROUND AND OBJECTIVES: Since the relatively recent discovery of the endocannabinoid system (ECS) and its fundamental role in regulating other systems, the subject has aroused interest in all areas of health, including Dentistry. Among the possible uses and benefits of cannabinoids are their performance in pain and its predisposing or perpetuating factors, such as bruxism and sleep disorders. Although the literature is still scarce, the mechanisms of action and satisfactory results of cannabinoids and other cannabis derivatives in these situations already allow their safe prescription. The objective of this study was to verify the current evidence on the use of cannabis derivatives in orofacial pain (OFP), reviewing what is known, to date, about the ECS and the prospects for its use with support and criteria.
CONTENTS: This research carried out a brief review of the cannabis plant history, addressing issues such as prejudice, prohibitions and interests, as well as its therapeutic use. Then, a review on ECS and its mechanisms of interest in OFP was presented. Next, the products derived from the plant and their effects, indications, contraindications, adverse effects, drug interactions, peculiarities and perspectives were discussed.
CONCLUSION: The more knowledge is gained about the ECS and the therapeutic benefits of cannabis components and derivatives, the greater the conviction that a new therapeutic frontier has indeed emerged. The growing number of good outcomes, including cases of OFP, obtained through well-conducted studies, brings a mixture of satisfaction and excitement. No therapy will achieve good results if it does not start from an accurate diagnosis. Thus, it is of the utmost importance to know the ECS, the products and derivatives of the plant, the synthetic cannabinoids, their indications and effects. New studies are necessary and, at this moment, it can be said that the perspectives are very good and a new and challenging horizon is emerging.

Keywords

Cannabidiol, Cannabis, Orofacial pain, Endocannabinoids, Dentistry

Resumo

JUSTIFICATIVA E OBJETIVOS: Desde a descoberta relativamente recente do sistema endocanabinoide (SEC) e seu papel fundamental da regulação de outros sistemas, o assunto tem despertado interesse de todas as áreas da saúde, incluindo-se a Odontologia. Dentre as possíveis utilizações e benefícios dos canabinoides, está sua atuação na dor e seus fatores predisponentes ou perpetuadores, como o bruxismo e os distúrbios do sono. Embora a literatura seja ainda escassa, os mecanismos de ação e resultados satisfatórios dos canabinoides e demais derivados da cannabis nessas situações já permitem sua prescrição com segurança. O objetivo deste estudo foi verificar as atuais evidências sobre a utilização de derivados da cannabis nas dores orofaciais (DOFs), revisando o que se sabe, até o momento, sobre o SEC e as perspectivas de sua utilização com respaldo e critério.
CONTEÚDO: Esta pesquisa realizou uma breve revisão da história da planta cannabis, abordando temas como preconceito, proibições e interesses, além de sua utilização terapêutica. Em seguida, foi apresentada uma revisão sobre o SEC e seus mecanismos de interesse na DOF. Na sequência, foram discutidos os produtos derivados da planta e seus efeitos, indicações, contraindicações, efeitos adversos, interações farmacológicas, peculiaridades e perspectivas. 
CONCLUSÃO: Quanto mais são adquiridos conhecimentos sobre o SEC e os benefícios terapêuticos dos componentes e derivados da cannabis, mais há um convencimento de que surgiu, de fato, uma nova fronteira terapêutica. O número crescente de bons desfechos, incluindo casos de DOF, obtidos através de estudos bem conduzidos, traz um misto de satisfação e empolgação. Nenhuma terapia obterá bons resultados se não partir de um diagnóstico preciso. Assim, é de suma importância que se conheça o SEC, os produtos e derivados da planta, os canabinoides sintéticos, suas indicações e efeitos. Novos estudos são necessários e, nesse momento, pode-se afirmar que as perspectivas são muito boas e um novo e desafiador horizonte está despontando.

Palavras-chave

Canabidiol, Cannabis, Dor orofacial, Endocanabinoides, Odontologia

References

1 Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833.

2 Kalant H. Medicinal use of cannabis: History and current status. Pain Res Manag. 2001;6(2):80-91.

3 Di Marzo V. The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res. 2009;60(2):77-84.

4 Bénard G, Massa F, Puente N, Lourenço J, Bellocchio L, Soria-Gómez E, Matias I, Delamarre A, Metna-Laurent M, Cannich A, Hebert-Chatelain E, Mulle C, Ortega-Gutiérrez S, Martín-Fontecha M, Klugmann M, Guggenhuber S, Lutz B, Gertsch J, Chaouloff F, López-Rodríguez ML, Grandes P, Rossignol R, Marsicano G. Mitochondrial CB 1 receptors regulate neuronal energy metabolism. Nat Neurosci. 2012;15(4):558-64.

5 Izzo AA, Sharkey KA. Pharmacology e therapeutics cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126(1):21-38.

6 Malfitano AM, Basu S, Maresz K, Bifulco M, Dittel BN. What we know and don’t know about the cannabinoid receptor 2 (CB2). Semin Immunol. 2014;26(5):369-79.

7 Trusler AR, Clark AK, Sivamani RK, Shi VY. The endocannabinoid system and its role in eczematous dermatoses. Dermatitis. 2017;28(1):22-32.

8 Schilling S, Melzer R, McCabe PF. Cannabis sativa. Curr Biol. 2020;30(1):R8-9.

9 Vučkovic S, Srebro D, Vujovic KS, Vučetic Č, Prostran M. Cannabinoids and pain: new insights from old molecules. Front Pharmacol. 2018;9:1259.

10 Romero P, Peris A, Vergara K, Matus JT. Comprehending and improving cannabis specialized metabolism in the systems biology era. Plant Sci. 2020;298:110571.

11 Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. 2021;22(17):1-42.

12 Grossman S, Tan H, Gadiwalla Y. Cannabis and orofacial pain: a systematic review. Br J Oral Maxillofac Surg. 2022;60(5):e677-90.

13 Neves GSML, Macedo P, Gomes MM. Transtornos do sono: Atualização (1/2). Rev Bras Neurol. 2017;53(3):19-30.

14 Bacelar A, Pinto Jr LR. Insônia do Diagnóstico ao tratamento: III Consenso Brasileiro de Insônia. Associação brasileira do sono. 2013.

15 Nascimento AGTP, Dalcin MF. Uso terapêutico da Cannabis sativa: uma breve revisão. Braz J Surg Clin Res. 2019;27(2):164-9.

16 Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007;9(4):413-30.

17 Votrubec C, Tran P, Lei A, Brunet Z, Bean L, Olsen BW, Sharma D. Cannabinoid therapeutics in orofacial pain management: a systematic review. Aust Dent J. 2022;67(4):314-27.

18 Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, Haroutounian S, Krane E, Rice ASC, Rowbotham M, Wallace M, Eccleston C. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl 1):S45-S66.

19 Haroutounian S, Arendt-Nielsen L, Belton J, Blyth FM, Degenhardt L, Di Forti M, Eccleston C, Finn DP, Finnerup NB, Fisher E, Fogarty AE, Gilron I, Hohmann AG, Kalso E, Krane E, Mohiuddin M, Moore RA, Rowbotham M, Soliman N, Wallace M, Zinboonyahgoon N, Rice ASC. International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(Suppl 1):S117-S124.

20 Crocq MA. History of Cannabis and endocannabinoid system. Dialogues Clin Neurisci. 2020;22(3):223-8.

21 Grieco M. Cannabis Medicinal: baseada em fatos. Rio de Janeiro: Editora Agir; 2021.

22 Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-13.

23 Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-9.

24 Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, Lichtman AH. The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology. 2018;43(1):52-79.

25 Nitecka-Buchta A, Nowak-Wachol A, Wachol K, Walczyńska-Dragon K, Olczyk P, Batoryna O, Kempa W, Baron S. Myorelaxant Effect of transdermal cannabidiol application in patients with tmd: a randomized, double-blind trial. J Clin Med. 2019;8(11):1886.

26 Almeida DL, Devi LA. Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect. 2020;8(6):e00682.

27 Ranieri R, Marasco D, Bifulco M, Malfitano AM. Phytocannabinoids and cannabimimetic drugs: recent patents in central nervous system disorders. Recent Pat CNS Drug Discov. 2016;10(2):157-77.

28 Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152(7):1092-101.

29 Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Arch Oral Biol. 2019;104(1):33-9.

30 Nutt DJ, Phillips LD, Barnes MP, Brander B, Curran HV, Fayaz A, Finn DP, Horsted T, Moltke J, Sakal C, Sharon H, O’Sullivan SE, Williams T, Zorn G, Schlag AK. A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products. Cannabis Cannabinoid Res. 2022;7(4):482-500.

31 Hossain MZ, Ando H, Unno S, Kitagawa J. Targeting peripherally restricted cannabinoid receptor 1, cannabinoid receptor 2, and endocannabinoid-degrading enzymes for the treatment of neuropathic pain including neuropathic orofacial pain. Int J Mol Sci. 2020;21(4):1423.

32 Sessle BJ. Editorial: Are cannabinoids effective for orofacial pain States? J Oral Facial Pain Headache. 2015;29:5-6.

33 McDonough P, McKenna JP, McCreary C, Downer EJ. Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol. 2014;55:72-8.

34 Gajofatto A. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. Mult Scler Relat Disord. 2016;8:64-5.

35 Pereira SR, Tello Velasquez J, Duggan S, Ivanisevic B, McKenna JP, McCreary C, Downer EJ. Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: Focus on the actions of cannabinoids. Eur J Neurosci. 2022;55(4):1032-50.

36 Gambino A, Cabras M, Panagiotakos E, Calvo F, Macciotta A, Cafaro A, Suria M, Haddad GE, Broccoletti R, Arduino PG. Evaluating the suitability and potential efficiency of cannabis sativa oil for patients with primary burning mouth syndrome: a prospective, open-label, single-arm pilot study. Pain Med. 2021;22(1):142-51.

37 Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, Olver I, Walsh A, McGregor I, Cheung Y, Tognela A, Hahn C, Briscoe K, Aghmesheh M, Fox P, Abdi E, Clarke S, Della-Fiorentina S, Shannon J, Gedye C, Begbie S, Simes J, Stockler M. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553-60.

38 Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46(2):207-18.

39 dos Santos GG, Dias EV, Teixeira JM, Athie MC, Bonet IJ, Tambeli CH, Parada CA. The analgesic effect of dipyrone in peripheral tissue involves two different mechanisms: neuronal K(ATP) channel opening and CB(1) receptor activation. Eur J Pharmacol. 2014;741:124-31.

40 Dos Santos GG, Vieira WF, Vendramini PH, Bassani da Silva B, Fernandes Magalhães S, Tambeli CH, Parada CA. Dipyrone is locally hydrolyzed to 4-methylaminoantipyrine and its antihyperalgesic effect depends on CB2 and kappa-opioid receptors activation. Eur J Pharmacol. 2020;874:173005.

41 Duarte Souza JF, Lajolo PP, Pinczowski H, Del Giglio A. Adjunct dipyrone in association with oral morphine for cancer-related pain: the sooner the better. Support Care Cancer. 2007;15(11):1319-23.

42 Roveroni RC, Parada CA, Cecília M, Veiga FA, Tambeli CH. Development of a behavioral model of TMJ pain in rats: the TMJ formalin test. Pain. 2001;94(2):185-91.

43 Burgos E, Pascual D, Martín MI, Goicoechea C. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests. Eur J Pain. 2010;14(1):40-8.

44 Wong H, Hossain S, Cairns BE. Delta-9-Tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation. Eur J Pain. 2017;21(10):1732-42.

45 Rofaeel M, Chow JC, Cioffi I. The intensity of awake bruxism episodes is increased in individuals with high trait anxiety. Clin Oral Investig. 2021;25(5):3197-206.

46 Fliegel DK, Lichenstein SD. Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety. Psychiatry Res Commun. 2022;2(4):100074.

47 Pina-Escudero SD, Okada de Oliveira M, Snyder A, Miller BL. Cannabidiol in the management of bruxism in behavioral variant of frontotemporal degeneration. Neurocase. 2021;27(2):209-11.

48 Umpreecha C, Bhalang K, Charnvanich D, Luckanagul J. Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial. BMC Complement Med Ther. 2023;23(1):57.

49 Cuba LF, Salum FG, Cherubini K, Figueiredo MAZ. Cannabidiol: an alternative therapeutic agent for oral mucositis? J Clin Pharm Ther. 2017;42:245-50.

50 Li L, Xuan Y, Zhu B, Wang X, Tian X, Zhao L, Wang Y, Jiang X, Wen N. Protective effects of cannabidiol on chemotherapy-induced oral mucositis via the Nrf2/keap1ARE signaling pathways. Oxid Med Cell Longev. 2022;2022:4619760.

51 Liu Y, Qi X, Wang Y, Li M, Yuan Q, Zhao Z. Inflammation-targeted cannabidiol-loaded nanomicelles for enhanced oral mucositis treatment. Drug Deliv. 2022;29(1):1272-81.

52 Jirasek P, Jusku A, Simanek V, Frankova J, Storch J, Vacek J. Cannabidiol and periodontal inflammatory disease: a critical assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022;166(2):155-60.

53 Abidi AH, Abhyankar V, Alghamdi SS, Tipton DA, Dabbous M. Phytocannabinoids regulate inflammation in IL-1β-stimulated human gingival fibroblasts. J Periodontal Res. 2022;57(6):1127-38.

54 Napimoga MH, Benatti BB, Lima FO, Alves PM, Campos AC, Pena-Dos-Santos DR, Severino FP, Cunha FQ, Guimarães FS. Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int. Immunopharmacol. 2009;9:216-22.

55 Vasudevan K, Stahl V. Cannabinoids infused mouthwash products are as effective as chlorhexidine on inhibition of total-culturable bacterial content in dental plaque samples. J Cannabis Res. 2020;2(1):20.

56 Aqawi M, Sionov RV, Gallily R, Friedman M, Steinberg D. Anti-biofilm activity of cannabigerol against Streptococcus mutans. Microorganisms. 2021;9(10):2031. (A)

57 Aqawi M, Sionov RV, Gallily R, Friedman M, Steinberg D. Anti-bacterial properties of cannabigerol toward Streptococcus mutans. Front Microbiol. 2021;12:656471.(B)

58 Aqawi M, Steinberg D, Feuerstein O, Friedman M, Gingichashvili S. Cannabigerol effect on Streptococcus mutans biofilms-a computational approach to confocal image analysis. Front Microbiol. 2022;13:880993.

59 Kalliomäki J, Segerdahl M, Webster L, Reimfelt A, Huizar K, Annas P, Karlsten R, Quiding H. Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal. Scand J Pain. 2013;4(1):17-22.

60 Ostenfeld T, Price J, Albanese M, Bullman J, Guillard F, Meyer I, Leeson R, Costantin C, Ziviani L, Nocini PF, Milleri S. A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin J Pain. 2011;27(8):668-76.

61 Sullivan SR, Hammad Y, Neal TW, Schlieve T. Cannabidiol and hemp oils: Potential applications in oral and maxillofacial surgery. J Am Dent Assoc. 2022;153(12):1111-3.

62 Kamali A, Oryan A, Hosseini S, Ghanian MH, Alizadeh M, Baghaban Eslaminejad M, Baharvand H. Cannabidiol-loaded microspheres incorporated into osteoconductive scaffold enhance mesenchymal stem cell recruitment and regeneration of critical-sized bone defects. Mater Sci Eng C Mater Biol Appl. 2019;101:64-75.

63 Li L, Feng J, Sun L, Xuan YW, Wen L, Li YX, Yang S, Zhu B, Tian XY, Li S, Zhao LS, Dang RJ, Jiao T, Zhang HS, Wen N. Cannabidiol promotes osteogenic differentiation of bone marrow mesenchymal stem cells in the inflammatory microenvironment via the CB2-dependent p38 MAPK signaling pathway. Int J Stem Cells. 2022;15(4):405-14.

64 Qi X, Liu C, Li G, Luan H, Li S, Yang D, Zhou Z. Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021;109:103673.

65 Yu L, Zeng L, Zhang Z, Zhu G, Xu Z, Xia J, Weng J, Li J, Pathak JL. Cannabidiol rescues TNF-α-inhibited proliferation, migration, and osteogenic/odontogenic differentiation of dental pulp stem cells. Biomolecules. 2023;13(1):118.

66 Gottschling S, Ayonrinde O, Bhaskar A, Blockman M, D’Agnone O, Schecter D, Suárez Rodríguez LD, Yafai S, Cyr C. Safety considerations in cannabinoid-based medicine. Int J Gen Med. 2020;13:1317-33.

67 Arnold JC. A primer on medicinal cannabis safety and potential adverse effects. Aust J Gen Pract. 2021;50(6):345-50.

68 Antoniou T, Bodkin J, Ho JM. Drug interactions with cannabinoids. CMAJ. 2020;192(9):E206.

69 MacCallum CA, Lo LA, Boivin M. Is medical cannabis safe for my patients? A practical review of cannabis safety considerations. Eur J Intern Med. 2021;89:10-8.

70 Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, Gefroh HA, Devane CL. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther. 2006;317(2):850-7.

71 Bhaskar A, Bell A, Boivin M, Briques W, Brown M, Clarke H, Cyr C, Eisenberg E, de Oliveira Silva RF, Frohlich E, Georgius P, Hogg M, Horsted TI, MacCallum CA, Müller-Vahl KR, O’Connell C, Sealey R, Seibolt M, Sihota A, Smith BK, Sulak D, Vigano A, Moulin DE. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021;3(1):22.

72 Anand U, Pacchetti B, Anand P, Sodergren MH. Cannabis-based medicines and pain: a review of potential synergistic and entourage effects. Pain Manag. 2021;11(4):395-403.

73 Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167-79.

74 Gallily R, Yekhtin Z, Hanuš LO. Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol. Pharmacol. Pharm. 2015;6:75.
 


Submitted date:
03/18/2023

Accepted date:
06/23/2023

6555361fa953952b3f592d32 brjp Articles

BrJP

Share this page
Page Sections